We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
EZZ Life Science Holdings Limited is a household & personal products business based in Australia. EZZ Life Science shares (EZZ) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. EZZ Life Science has a trailing 12-month revenue of around $22.3 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Cheap broker fees
| 52-week range | $0.38 - $1.425 |
|---|---|
| 50-day moving average | $0.4593 |
| 200-day moving average | $0.5479 |
| Target price | N/A |
| PE ratio | 8.5 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $0.06 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.51
| 1 week (2021-09-20) | -7.27% |
|---|---|
| 1 month (2021-08-27) | 14.61% |
| 3 months (2021-06-25) | 14.61% |
| 6 months (2021-03-26) | -32.00% |
Valuing EZZ Life Science stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of EZZ Life Science's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
EZZ Life Science's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 9x. In other words, EZZ Life Science shares trade at around 9x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
EZZ Life Science's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.8 million (£0.0 million).
The EBITDA is a measure of a EZZ Life Science's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $22.3 million |
|---|---|
| Operating margin TTM | 12.33% |
| Gross profit TTM | $12.5 million |
| Return on assets TTM | 18.85% |
| Return on equity TTM | 32.44% |
| Profit margin | 9.11% |
| Book value | 0.241 |
| Market capitalisation | $21.4 million |
TTM: trailing 12 months
We're not expecting EZZ Life Science to pay a dividend over the next 12 months.
EZZ Life Science Holdings Limited provides skin care and consumer health products to retailers and consumers in Australia and internationally. It is involved in the wholesale distribution of EAORON branded skin care products to pharmacies, supermarkets, and specialist retailers, as well as to other grocery retailers and on-line retailers. The company also develops, produces, and distributes a range of consumer health products under the EZZ brand to retailers and consumers through online and offline channels. EZZ Life Science Holdings Limited was founded in 2018 and is headquartered in Silver Water, Australia.
Everything we know about the Cosmos Exploration IPO, plus information on how to buy in.
Shares in BNPL provider Zip Co have slipped more than 13% in the last 6 months.
Shares in electricity giant AGL Energy are down 60% in the last 12 months.
Everything we know about the Dundas Minerals IPO, plus information on how to buy in.
Everything we know about the Kalgoorlie Gold Mining IPO, plus information on how to buy in.
We look at some of the biggest and best performing iron ore stocks in Australia.
Shares in the major banks have risen more than 50% in the last 12 months.
Steps to owning and managing China Evergrande Group shares from Australia.
Everything we know about the Hamelin Gold IPO, plus information on how to buy in.
Everything we know about the Lykos Metals IPO, plus information on how to buy in.
